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TB in adults. The conversion of XMP to GMP is catalyzed by guaA-encoded GMP synthetase (GMPS), and
deletions in the Shiguella ﬂexneri guaBA operon led to an attenuated auxotrophic strain. Here we present
the cloning, expression, and puriﬁcation of recombinant guaA-encoded GMPS from Mycobacterium tuber-
culosis (MtGMPS). Mass spectrometry data, oligomeric state determination, steady-state kinetics, isother-
mal titration calorimetry (ITC), and multiple sequence alignment are also presented. The homodimeric
MtGMPS catalyzes the conversion of XMP, MgATP, and glutamine into GMP, ADP, PPi, and glutamate.
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mate in the absence of substrates. ITC data suggest random order of binding of substrates, and PPi is the
last product released. Sequence comparison analysis showed conservation of both Cys-His-Glu catalytic
triad of N-terminal Class I amidotransferase and of amino acid residues of the P-loop of the N-type ATP
pyrophosphatase family.
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evier OA license.ies have shown that each year up to 9.4 million people are infected
with Mycobacterium tuberculosis, the main aetiological agent of TB,
causing approximately 3 million deaths [1]. The efﬁcacy of TB che-
motherapy has been diminished due to the emergence of multi-
drug-resistant (MDR), extensively drug-resistant (XDR) [2], and
totally drug-resistant (TDR) [3] strains. The global burden of TB
remains high, particularly in countries with high prevalence of
drug-resistance and TB-HIV co-infection [4]. Despite important
achievements, the control of TB epidemic remains elusive, which
underlines the need for new strategies to combat TB.
Although the only vaccine currently in use, bacille Calmette-
Guérin (BCG), protects very young children from invasive forms
of TB, adolescents and adults are variably protected and remain
susceptible to pulmonary diseases caused by M. tuberculosis [5].
The synthesis of guanosine 50-monophosphate (GMP) from inosine
50-monophosphate (IMP) requires both guaB-encoded inosine
monophosphate dehydrogenase (IMPDH) and guaA-encoded gua-
nosine monophosphate synthetase (GMPS). Deletions in the Shigu-
ella ﬂexneri guaBA operon led to an attenuated auxotrophic strain
that conferred both immunogenicity and safety in volunteers
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M. tuberculosis H37Rv guaB and guaA genes are not located in a
bicistronic operon, but rather present as independent loci [9]. Of
the three IMPDH paralogs in M. tuberculosis (guaB1, Rv1843c;
guaB2, Rv3411c; and guaB3, Rv3410c), guaB2 has been shown to
encode a protein with IMPDH activity that was tested as target
for triazole-linked enzyme inhibitors [10].
GMPS (EC 6.3.5.2) is a key enzyme in both purine de novo syn-
thesis and salvage pathways [11,12] of guanine nucleotides, and
belongs to a G-type amidotransferase family that catalyzes the
conversion of xanthosine 50-monophosphate (XMP) and L-gluta-
mine in the presence of H2O, adenosine 50-triphosphate (ATP),
and Mg2+ into GMP, pyrophosphate (PPi), adenosine 50-monophos-
phate (AMP), and L-glutamate (Fig. 1) [13,14]. In both prokaryotes
and eukaryotes, the tertiary structure of GMPS is formed by two
domains with distinct functions. The C-terminal ATP pyrophospha-
tase (ATPPase) domain catalyses the condensation of XMP with
ATP, and the N-terminal glutamine amidotransferase (glutamin-
ase; GATase) domain catalyses the hydrolysis of glutamine to
ammonia and glutamate [15]. Biochemical studies have been
reported for GMPS enzymes from human [13], Escherichia coli
[16], F. tularensis [8], Pyrococcus horikoshii [17], and Plasmodium fal-
ciparum [15]. The guaA-encoded protein has been predicted to be
essential for in vitro growth of M. tuberculosis based on transpo-
son-site hybridization studies [18]. However, no formal biochemi-
cal data have been presented to show whether or not the guaA
gene codes for a protein with GMPS activity as predicted by in silico
analysis of M. tuberculosis genome sequence. To pave the way for
further efforts to show that deletion of the guaA gene may result
in an auxotrophic M. tuberculosis strain for guanine with attenu-
ated virulence, biochemical characterization of the guaA-encoded
protein is worth pursuing. Accordingly, here we describe the clon-
ing, expression, puriﬁcation to homogeneity, mass spectrometry,
oligomeric state determination, steady-state kinetics, isothermal
titration calorimetry (ITC), and multiple sequence alignment of
M. tuberculosis GMPS (MtGMPS). It is hoped that these data may
contribute to functional efforts towards a better understanding of
the basic biology of M. tuberculosis.Materials and methods
PCR ampliﬁcation, cloning, and recombinant protein expression
Synthetic oligonucleotide primers (50-tgcatatggtgcagcctgctga-
catcgacg-30 and 50-ggggatcctcactcccactcgatggtggc-30) complemen-
tary to the amino-terminal coding and carboxy-terminal
noncoding strands of the M. tuberculosis guaA (Rv3396c) gene [9]
were designed to contain, respectively, NdeI and BamHI restriction
sites (in bold). These primers were used to amplify the guaA struc-
tural gene (1578 bp) from M. tuberculosis H37Rv genomic DNA
using standard PCR conditions (Perkin–Elmer), in the presence of
5% dimethyl sulfoxide (DMSO; ﬁnal concentration). The PCRFig. 1. MtGMPS catalyzes the irreversible conversion of XMP into GMP through a reactio
XMP via an adenyl-XMP intermediate, generating PPi, AMP, and glutamate.roduct was digested with NdeI and BamHI (New England Biolabs),
and ligated into a pET23a(+) expression vector (Novagen). The
DNA sequence of the cloned fragment, expected to correspond to
the M. tuberculosis guaA gene, was determined by automated
DNA sequencing to conﬁrm gene identity and integrity, and ensure
that no mutations were introduced by the PCR ampliﬁcation step.
The recombinant pET23a(+)::guaA plasmid was introduced into
E. coli BL21(DE3) (Novagen) electrocompetent host cells by electro-
poration, and the transformed cells were selected on Luria–Bertani
(LB) agar plates containing 50 lg mL1 ampicillin. LB medium
(2.5 L) containing 50 lg mL1 ampicillin was inoculated with
single colonies, and the bacterial culture grown at 180 rpm and
37 C for 6 h after reaching an OD600nm = 0.4–0.6, without isopro-
pyl-b-D-thiogalactopyranoside (IPTG) induction. Cells were har-
vested by centrifugation at 4,000g for 30 min at 4 C and stored
at20 C. Soluble and insoluble fractions were analyzed by 12% so-
dium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–
PAGE) [19].
Protein puriﬁcation
All puriﬁcation steps were performed using an Äkta Puriﬁer (GE
Healthcare) system at 4 C. Approximately 2 g of wet cell paste
were suspended in 10 mL of 50 mM tris(Hydroxymethyl)amino-
methane (Tris) pH 7.5 (buffer A) and gently stirred for 30 min in
the presence of 0.2 mg mL1 lysozyme (Sigma Aldrich; ﬁnal con-
centration). Cells were disrupted by sonication with 10 pulses of
10 s each at 60% amplitude with a 13 mm probe, and cell debris
was removed by centrifugation at 48,000g for 30 min. To precipi-
tate nucleic acids and ribonuclear proteins, the supernatant was
treated with 1% (wt./vol.) streptomycin sulfate (ﬁnal concentra-
tion) for 30 min and centrifuged at 48,000g for 30 min. The super-
natant was dialyzed against buffer A and loaded on a Q-Sepharose
Fast Flow (GE Healthcare) anion exchange column, pre-equili-
brated with buffer A. Adsorbed protein elution was carried out
using a 0–0.4 M NaCl linear gradient in buffer A, and the fractions
containing the target protein were pooled, concentrated using an
Amicon ultraﬁltration membrane (10 kDa molecular weight cut-
off), and loaded on a HiLoad Superdex 200 (GE Healthcare) size
exclusion column, pre-equilibrated with buffer A, and isocratically
eluted at a 0.5 mL min1 ﬂow rate. The fractions containing the tar-
get protein were pooled, (NH4)2SO4 was added to a ﬁnal concentra-
tion of 1 M, the solution was clariﬁed by centrifugation at 48,000g
for 30 min, and the supernatant was loaded on a Butyl-Sepharose
High Performance (GE Healthcare) hydrophobic interaction col-
umn, pre-equilibrated with buffer A containing 1 M (NH4)2SO4. Ad-
sorbed protein was eluted using 1–0 M (NH4)2SO4 linear gradient,
yielding homogeneous recombinant protein which was dialyzed
against buffer A and stored at 80 C. Pooled fractions of all puri-
ﬁcation steps were analyzed by SDS–PAGE and enzyme activity
measurements. Protein concentration was determined by the
method of Bradford [20] using the Bio-Rad Protein Assay Kit
(Bio-Rad) and bovine serum albumin as standard.n that requires ATP and involves the transfer of an amino group from glutamine to
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solution
Protein identity and subunit molecular mass of homogeneous
recombinant MtGMPS were assessed by mass spectrometry, and
data processing carried out using the MagTran software [21]. The
molecular mass of native recombinant MtGMPS was determined
using a Superdex 200 HR 10/30 (GE Healthcare) size exclusion col-
umn, pre-equilibrated with 50 mM Tris pH 7.5 containing 200 mM
NaCl, and a ﬂow rate of 0.4 mL min1 was employed for isocratic
protein elution. The LMW and HMW Gel Filtration Calibration Kits
(GE Healthcare) were used to prepare a calibration curve. The elu-
tion volumes (Ve) of standard proteins (ferritin, catalase, aldolase,
coalbumin, ovalbumin, and ribonuclease A) were used to calculate
their corresponding partition coefﬁcient (Kav; Eq. (1)). Blue dextran
2000 (GE Healthcare) was used to determine the void volume (Vo).
Vt is the total bed volume of the column. The Kav value for each pro-
tein was plotted against their corresponding molecular mass. Pro-
tein elution was monitored at 215, 254, and 280 nm.
Kav ¼ Ve  VoVt  Vo ð1ÞApparent steady-state kinetic parameters
MtGMPS activity was continuously monitored by measuring
the decrease in absorbance at 290 nm upon conversion of
XMP (e = 3834 M1cm1) to GMP (e = 2686 M1cm1) using an
UV-2550 spectrophotometer (Shimadzu). A De290 value of
1148 M1cm1 was employed to calculate the rate of MtGMPS-
catalyzed product formation. All activity assays were performed
at 40 C in 50 mM Tris pH 7.5, unless stated otherwise, and assay
mixtures contained XMP, ATP, glutamine (or (NH4)2SO4), MgCl2
(20 mM), and EDTA (0.3 mM), in a total reaction volume of
0.5 mL. Measurements of enzyme activity were initiated by the
addition of 16 lg of MtGMPS (protein concentration that yielded
linear time courses). Each individual initial rate datum was the
average of duplicate or triplicate measurements, and all data were
analyzed by nonlinear regression using the SigmaPlot software
(Systat Software, Inc.). One unit of enzyme activity (U) was deﬁned
as the amount of enzyme catalyzing the conversion of 1 lmol of
substrate into product per minute.
The pH optimum value for MtGMPS reaction was determined by
measuring speciﬁc activity in 50 mM Tris buffer at pH values rang-
ing from 6.0 to 9.5, with increments of 0.5 pH units, at 40 C. To
probe the effect of temperature on enzyme speciﬁc activity, the
MtGMPS-catalyzed reaction was monitored at 25, 30, 37, and
40 C. Both (pH and temperature) experiments were performed
keeping all substrates at saturating concentrations (0.15 mM
XMP, 1 mM ATP, and 5 mM glutamine) and initiated by the addi-
tion of MtGMPS into the reaction mixture.
Apparent kinetic constants for XMP, ATP, and glutamine (and
NHþ4 , as (NH4)2SO4) were determined by varying the concentration
of one substrate while keeping the other two at saturating concen-
trations. The data were either ﬁtted to the Michaelis–Menten equa-
tion (Eq. (2)) for a hyperbolic saturation curve, to the Hill equation
(Eq. (3)) for a sigmoidal saturation curve, or to the substrate inhi-
bition equation (Eq. (4)) [22,23]. For these equations, v is the mea-
sured reaction velocity, V is the maximal velocity, S is the substrate
concentration, KM is the Michaelis constant, Ki is the dissociation
constant for substrate inhibition, n is the Hill coefﬁcient (indicating
the cooperative index), and K0.5 is the substrate concentration in
which v = 0.5V.
V ¼ V ½S
KM þ S ð2ÞV ¼ V ½S
n
Kn0:5 þ ½Sn
ð3Þ
V ¼ VS
KM þ S 1þ SK1
  ð4ÞMtGMPS activity dependence on increasing Mg2+ concentration
To investigate the inﬂuence of Mg2+ on MtGMPS speciﬁc activ-
ity, the enzyme-catalyzed chemical reaction was monitored at
varying concentrations of MgCl2, keeping all substrates at saturat-
ing concentrations in the presence of 0.3 mM EDTA. Apparent stea-
dy-state kinetic constants were obtained by ﬁtting the data to the
Hill equation (Eq. (3)) for a sigmoidal saturation curve. To assess
whether or not there may be an additional Mg2+-binding site in
MtGMPS, MgCl2 was ﬁxed at 2 mM, whereas ATP concentration
was varied. Standard assay conditions were used for activity mea-
surements, except that EDTA was omitted from the reaction mix-
ture. Eqs. (5) and (6) were solved simultaneously to estimate
MgATP concentration [24]. For these equations, [M]t, [ATP]t,
[MATP], [M], and [H] represent the total Mg2+, total ATP, total
MgATP2, free Mg2+, and free hydrogen ion concentrations, respec-
tively. K1, K2, and KH represent the dissociation constants for
MgATP2, MgHATP, and HATP3, respectively. The values for K1,
K2, and KH were, respectively, 1.37  105, 2  103, and 1.12 
107 as given by Nakamura and Lou [14]. The MtGMPS speciﬁc
activity values were plotted against MgATP2, free Mg2+, and free
ATP concentrations
½M ¼ ½Mt  ½MATP 1þ
K1½H
K2KH
  
ð5Þ
½MATP ¼ ½ATP1
1þ K1½M þ K1 ½H½MKH þ
K1 ½H
K2KH
ð6ÞATPPase activity measurements
MtGMPS ATPPase activity was evaluated by the EnzCheck Pyro-
phosphate Assay Kit (Invitrogen), which couples the conversion of
PPi into two equivalents of inorganic phosphate (Pi), catalyzed by
inorganic pyrophosphatase, followed by phosphorolysis of 2-amino-
6-mercapto-7-methylpurine ribonucleoside (MESG) catalyzed by
purine nucleoside phosphorylase (PNP) to form ribose 1-
phosphate and 2-amino-6-mercapto-7-methylpurine, which is de-
tected by measuring the increase in absorbance at 360 nm
(e = 11,000 M1 cm1) [25,26]. The reaction mixture was previ-
ously incubated for 10 min to remove any Pi contamination, and
contained 50 mM Tris pH 7.5, 0.15 mM XMP, varying ATP concen-
tration, 20 mMMgCl2, 0.3 mM EDTA, and EnzCheck Pyrophosphate
Assay Kit buffer and enzymes (PNP and inorganic pyrophospha-
tase) at concentrations recommended by the supplier. All reactions
were initiated by the addition MtGMPS. ATP concentrations were
varied in the pre-incubated reaction mixture until saturation was
reached. The data were best ﬁtted to the substrate inhibition equa-
tion (Eq. (4)).
Isothermal titration calorimetry (ITC): measurements of ligand
binding and MtGMPS glutaminase activity
ITC experiments were carried out using an iTC200 Microcalo-
rimeter (Microcal, Inc., Northampton, MA). The reference cell
(200 lL) was loaded with Milli Q water for all experiments and
the sample cell (200 lL) was ﬁlled with MtGMPS at a concentration
of 80 lM. For each binding assay, the injection syringe (39.7 lL)
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tamate or PPi, or 3.5 mM for glutamine). The ligand binding iso-
therms were measured by direct titration (ligand into
macromolecule). Recombinant MtGMPS protein was prepared for
ITC experiments by dialyzing against 50 mM N-2-hydroxyethylpip-
erazine-N0-2-ethanesulfonic acid (Hepes) pH 7.5 containing 20 mM
MgCl2. The same buffer was used to prepare all ligand solutions
used in the kinetic assays, replacing Tris, which has high enthalpy
of ionization [27]. The stirring speed was set to 500 rpm at a tem-
perature of 40 C for all experiments. The ﬁrst titration injection
(0.5 lL), which was discarded for data analysis, was followed by
11 injections of 3.9 lL each at 180 s intervals. Control titrations
(ligand into buffer) were performed to subtract the heat of dilution
and mixing for each experiment prior to data analysis. The data
after peak integration of the isotherm generated by ITC were sub-
tracted by the control titration data and concentration normaliza-
tion (heat normalized to the molar ratio).
The DG (Gibbs free energy) of binding was calculated using the
relationship described in Eq. (7), in which R is the gas constant
(8.314 J K1 mol1), T is the temperature in Kelvin (T = C +
273.15), and Ka is the association constant at equilibrium. The en-
tropy of binding (DS) can also be determined by this mathematical
formula. Estimates for Ka and the binding enthalpy (DH) were re-
ﬁned by a standard Marquardt nonlinear regression method pro-
vided in the Origin 7 SR4 software (Microcal, Inc., Northampton,
MA)
DG ¼ RTIn Ka ¼ DH  TDS ð7Þ
The observed calorimetric enthalpies (DHcal) and the rate con-
stant for the reaction catalyzed by the MtGMPS glutaminase
domain in the absence of XMP and ATP was determined from the
thermograms (heat ﬂow as a function time) obtained in the
iTC200 Microcalorimeter at 40 C. The principles of ITC implemen-
tation were described elsewhere [28]. The reaction started by the
injection of 2 lL of 80 lM MtGMPS into the sample cell after 60 s
of initial delay and 900 s of spacing time between the ﬁrst and sec-
ond injections, in a ﬁnal concentration of 1.6 lM. The reaction con-
tained 50 mM Hepes pH 7.5, 20 mM MgCl2, 5 mM glutamine, and
enzyme at 80 lM initial concentration.
Multiple sequence alignment
The amino acid sequences of prokaryotic GMPS proteins that
have three-dimensional structures solved were included in the
alignment (E. coli (YP_001731437.1) and P. horikoshii (2DPL_B)).
The human (NP_003866.1) GMPS was also included in the align-
ment and compared with M. tuberculosis (CAB01027.1). Multiple
amino acid sequence alignment was performed by Clustal W
[29], using the Gonnet matrix for amino acid substitutions and
considering gap penalties, to identify essential residues for nucleo-
tide substrate(s) binding, as well as to infer possible similarities in
their mechanisms of catalysis. For alignment improvement, the
ATPPase sequence of GMPS from P. horikoshii that is encoded by
the ph1347 gene, whose structure has been reported, was also
analyzed.Results and discussion
M. tuberculosis guaA ampliﬁcation and cloning
The M. tuberculosis guaA (Rv3396c) gene was ampliﬁed using
standard PCR conditions in the presence of 5% DMSO in the reac-
tion mixture (data not shown). The DMSO co-solvent helps over-
come polymerase extension difﬁculties due to DNA secondary
structures and improves the denaturation of GC-rich DNAs [30],which is consistent with the 65.6% G+C content of the M. tubercu-
losis genome [9]. The PCR product consistent with the expected
size (1578 bp) was puriﬁed and inserted into the pET23a(+)
expression vector between the NdeI and BamHI restriction sites.
Nucleotide sequence analysis of the cloned DNA fragment con-
ﬁrmed the identity of the insert as the M. tuberculosis guaA coding
sequence and demonstrated that no mutations were introduced by
the PCR ampliﬁcation step.
Heterologous protein expression, puriﬁcation, and mass spectrometry
of homogeneous MtGMPS
MtGMPS was overexpressed in E. coli BL21(DE3) electrocompe-
tent host cells transformed with the pET-23a(+)::guaA recombi-
nant plasmid. SDS–PAGE analysis conﬁrmed the expression of a
protein in the soluble fraction with apparent subunit molecular
mass consistent with the one expected for MtGMPS (approxi-
mately 56 kDa), and showed that the highest yield of soluble
recombinant MtGMPS expression was obtained at 6 h of cell
growth after reaching an OD600nm = 0.4–0.6 at 37 C in LB medium
(Fig. S1, Supplementary Data), without IPTG addition. In the pET
vector system, target genes are positioned downstream of the
strong bacteriophage T7 late promoter. In agreement with the re-
sults presented here, high levels of protein expression in the ab-
sence of inducer have been shown to occur in the pET system
[31–33]. It has been proposed that leaky protein expression is a
property of the lac-controlled system when cells approach
stationary phase in complex medium and that cyclic adenosine
monophosphate, acetate, and low pH are required to achieve
high-level expression in the absence of IPTG induction, which
may be part of the general cellular response to nutrition limitation
[34]. However, more recently, it has been shown that unintended
induction in the pET system is due to the presence of as little as
0.0001% of lactose in the medium [35].
The overexpressed recombinant MtGMPS protein was puriﬁed
by a three-step protocol consisting of an anion exchange column
(Q-Sepharose Fast Flow), a size exclusion column (HiLoad Super-
dex 200), and a hydrophobic interaction column (Butyl-Sepharose
High Performance). SDS–PAGE analysis showed that MtGMPS was
apparently homogeneous (Fig. S2, Supplementary Data). This puri-
ﬁcation protocol yielded 10 mg of homogeneous recombinant pro-
tein from 2 g of wet cell paste, with an overall protein yield of 32%
(Table S1, Supplementary Data). Mass spectrometry analysis was
carried out to show identity and integrity of homogeneous recom-
binant MtGMPS. Mass spectrometry analysis of trypsin-digested
MtGMPS identiﬁed 82% of the enzyme primary sequence (Table
S2, Supplementary Data). Deconvoluted spectra of MtGMPS pre-
sented a single peak corresponding to an average subunit molecu-
lar mass value of (55,928.64 Da), suggesting removal of the
N-terminal methionine residue (theoretical = 56,027.60 Da)
(Fig. S3, Supplementary Data). The mass spectrometry analysis also
revealed no peak at the expected mass of E. coli GMPS (58,679 Da),
thus lending further support for homogeneity of recombinant pro-
tein. Recombinant MtGMPS was stored at 80 C in 50 mM Tris pH
7.5, as this buffer was found to be appropriate for further steady-
state enzyme activity measurements. No loss on speciﬁc activity
could be observed after storage for at least three months at this
temperature (data not shown).
Oligomeric state of MtGMPS
The molecular mass of native MtGMPS was determined by size
exclusion chromatography and yielded a single peak with elution
volume (12.35 mL) corresponding to 136.96 kDa, suggesting that
MtGMPS is a dimer in solution (136,960 Da/55928.64 Da ﬃ 2.4).
This result is in agreement with the oligomeric state of GMPS
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but differs from higher eukaryotes, including humans [14], which
are monomeric. The presence of a large insertion near the dimer-
ization domain in GMPS of higher eukaryotes seems to preclude di-
mer formation [36]. It has been suggested that the diversity in
oligomeric states of this class of enzyme may reﬂect different
modes of regulation and varied functions [15].Apparent steady-state kinetics
Prior to embarking on determining the apparent steady-state
kinetic parameters, the optimum pH value was determined.
MtGMPS activity measurements at saturating substrate concentra-
tions showed that the optimum pH value was 7.5 (Fig. 2). To allow
comparisons to be made between velocities of MtGMPS, human
[14], and E. coli [16,37] enzymes, speciﬁc activity values were
determined at various temperatures. Not surprisingly, MtGMPS
speciﬁc activity increased as a function of temperature up to
40 C (data not shown). Steady-state velocity measurements were
thus carried out at 40 C in 50 mM Tris pH 7.5.
Saturations curves for MtGMPS speciﬁc activity plotted against
increasing concentrations of XMP (Fig. 3A), ATP (Fig. 3B), glutamine
(Fig. 3C), and NHþ4 (Fig. 3C-inset) showed to obey distinct func-
tions. The apparent steady-state kinetic parameters are given in
Table 1. Fitting the sigmoidal data for XMP saturation curve to
Eq. (3) yielded values of 45 (±1) lM for the Hill constant (K0.5)
and 2.30 (±0.04) s1 for kcat, suggesting positive homotropic coop-
erative kinetics for XMP. A similar pattern has also been observed
for human GMPS isozymes, which have K0.5 values of 35.6 and
45.4 lM [14]. Interestingly, to the best of our knowledge, a sigmoi-
dal proﬁle for XMP saturation curve has never been observed for
GMPS enzymes of prokaryotes. Increasing XMP concentrations re-
sulted in inhibition of MtGMPS activity (data not shown). The lim-
iting value for the Hill coefﬁcient (n) is 2 as MtGMPS is a dimer in
solution. The n value of 2.4 thus indicates strong positive homotro-
pic cooperativity for XMP.
The saturation curve for NHþ4 was also sigmoidal (Fig. 3C-inset)
and ﬁtting the data to Eq. (3) yielded values of 13 (±1) mM for K0.5
and 1.02 (±0.04) s1 for kcat (Table 1). Interestingly, saturation
curves for increasing NHþ4 concentrations were shown to be hyper-
bolic for human (KM = 5.1 mM) [14], E. coli (KM = 41 or 293 mM)
[37], and P. falciparum (KM = 5.4 mM) [15] GMPS enzymes. As
shown for human GMPS [14], the catalytic constant is signiﬁcantlyFig. 2. Screening of MtGMPS speciﬁc activity as a function of pH. The experiment
was carried out in 50 mM Tris buffer at pH values ranging from 6.0 to 9.5, with
increments of 0.5 pH units, at 40 C.
Fig. 3. Apparent kinetic parameters for MtGMPS. Speciﬁc activity as a function of
the concentration of (A) XMP, (B) ATP, and (C) glutamine. Inset displays the speciﬁc
activity as a function of ammonia.lower for NHþ4 (kcat = 0.10 s
1) as compared to glutamine (kcat =
3.05 s1; Table 1), suggesting that the latter is likely to be the pre-
ferred physiological substrate for MtGMPS. The KM value for gluta-
mine (1.24 mM), derived from ﬁtting the hyperbolic saturation
curve data (Fig. 3C) to Eq. (2), is smaller than that found for
E. coli GMPS (13 mM) [37] and larger than those for human GMPS
isozymes (406 and 358 lM) [14].
Table 1
Apparent kinetic constants for MtGMPS at varying XMP, ATP, glutamine, and NHþ4
concentrations.
K05 (lM) KM (lM) Vmax (Umg1) kcat (s1)
XMP 45 ± 1 – 2.49 ± 0.04 2.30 ± 0.04
ATP – 27 ± 2 2.58 ± 0.04 2.39 ± 0.04
Glutamine – 1.24 (±0.06)  103 3.30 ± 0.05 3.05 ± 0.05
NHþ4 13 ± 1
* – 1.10 ± 0.04 1.02 ± 0.04
* The KM for NH
þ
4 is given in mM.
Fig. 4. MtGMPS enzyme activity dependence on Mg2+. All the assays were
performed using standard conditions, as described in the Section 2. (A) Activity of
MtGMPS with respect to Mg2+, at a ﬁxed concentration of ATP (2 mM). These data
were best ﬁtted the positive cooperativity equation (Eq. (3)). (B) Effect of varying
ATP concentration on MtGMPS activity at ﬁxed concentration of Mg2+ (2 mM), in
which (d) represents MtGMPS speciﬁc activity in Umg1, (j) [MgATP2], () free
[ATP], and (N) free [Mg2+].
6 T.M.A. Franco et al. / Archives of Biochemistry and Biophysics 517 (2012) 1–11The saturation curve for ATP in the presence of saturating con-
centrations of XMP and glutamine showed reduced MtGMPS activ-
ity at large (post-saturating) concentrations of ATP (Fig. 3B).
Accordingly, these data were ﬁtted to Eq. (4), yielding KM and kcat
values of 27 (±2) lM and 2.39 (±0.04) s1, respectively, for ATP
(Table 1). The substrate inhibition constant (Ki) was 21 ± 3 mM
for ATP, which is approximately 780-fold larger than the KM (Table
1). A similar proﬁle was observed for the mycobacterial enzyme
that catalyzes the previous step in the pathway, IMPDH [10]. Sub-
strate inhibition of M. tuberculosis IMPDH was attributed to the
formation of an IMPDH-XMP⁄:NAD complex, which is an interme-
diate of the reaction [38,39].
Activity dependence on Mg2+ concentration
To evaluate the Mg2+ metal requirement of MtGMPS, enzyme
activity measurements were carried out at increasing metal con-
centrations. The Mg2+ saturation curve was apparently sigmoidal
and the data were best ﬁtted to Eq. (3) (Fig. 4A), yielding a value
of a value of 2.67 for the Hill coefﬁcient (n), 1.18 ± 0.03 mM for
K0.5, and 1.96 ± 0.02s1 for kcat. These data suggest strong positive
homotropic cooperativity upon increasing concentrations of Mg2+.
Maximum speciﬁc activity was achieved at approximately 5 mM
Mg2+, which is 5-fold larger than the concentration of ATP
(1 mM) in the reaction mixture, suggesting that there may be an
additional binding site for Mg2+ in MtGMPS. Sigmoidal dependence
of enzyme activity on increasing Mg2+ concentration has also been
observed for human GMPS [14] and E. coli GMPS [37]. To try to
ascertain whether or not there is an additional Mg2+ binding site
in MtGMPS, ATP was varied in the presence of Mg2+ at a ﬁxed con-
centration of 2 mM (Fig. 4B), in the absence of EDTA. It is notewor-
thy that the maximum enzyme activity was not achieved at the
maximum MgATP concentration. In addition, after a maximum
value of 2.5 Umg1, the MtGMPS speciﬁc activity decreased as
free Mg2+ concentration decreased (Fig. 4B). These data suggest
that either free ATP competes for the MgATP binding site, which
is also consistent with the product inhibition showed in Fig. 3B,
or that the enzyme has an additional site for free Mg2+, whose
occupancy results in increasing enzyme activity. Although addi-
tional binding sites for free Mg2+ have been proposed for human
[14] and E. coli [37] GMPS proteins, whether or not there exists
an additional binding for free Mg2+ should await experimental evi-
dence on MtGMPS structure. At any rate, enzyme activity measure-
ments to determine the apparent steady-state kinetic parameters
for XMP, ATP, glutamine, and NHþ4 were carried out at ﬁxed-satu-
rating concentration of MgCl2 (20 mM).
ATPPase activity of MtGMPS
GMPS proteins consist of two catalytic units, a GATase domain
and an ATPPase domain. The GATase domain has glutaminase
activity. The ATPPase domain binds ATP and XMP, in the presence
of Mg2+, to form the activated adenyl-XMP intermediate with con-
comitant PPi formation [15,36,37]. As an attempt to determine
whether or not the ATPPase activity of MtGMPS is independentof GATase activity, measurements of PPi formation were carried
out by a coupled assay with PNP and pyrophosphatase in the
absence of glutamine and ﬁxed-saturating concentration of XMP
(0.15 mM). The data (Fig. 5) were best ﬁtted to the substrate inhi-
bition equation (Eq. (4)), yielding values of 56 (±6) lM for KM, 0.71
(±0.02) s1 for kcat, and 9 (±2) mM for Ki. These results suggest for-
mation of adenyl-XMP with concomitant release of PPi in the
absence of glutamine. The KM values in either the absence
(56 lM) or presence (27 lM) of glutamine are somewhat similar,
whereas the kcat value in the presence of glutamine (2.39 s1) is
larger than in the absence of glutamine (0.71 s1). These data
suggest that glutamine has no effect on the overall dissociation
constant of ATP, whereas it appears to increase the overall catalytic
rate of the ATPPase domain of MtGMPS.ITC: ligand binding and glutaminase activity
In order to determine the true steady-state kinetic parameters
and initial velocity patterns in double-reciprocal plots for MtGMPS,
enzyme activity measurements were made in the presence of vary-
ing glutamine (100–5055 lM) concentrations and several ﬁxed-
varied ATP (100–2000 lM) concentrations, while keeping XMP at
a ﬁxed (150 lM) concentration. However, the double-reciprocal
plots were curved upwards for ATP and showed a non-consistent
Fig. 5. MtGMPS speciﬁc activity as a function of ATP concentration without
glutamine in the reaction mixture reveals the release of PPi and the formation of
adenyl-XMP.
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shown), thereby precluding a proposal for MtGMPS enzyme mech-
anism based on measurements of dependence of steady-state
velocities on increasing ATP or glutamine concentrations. In addi-
tion, the dependence of MtGMPS on increasing XMP concentration
was sigmoidal.
To try to address the order of substrate addition and/or product
release, equilibrium binary complex formation were assessed by
ITC, determining the heat generated or consumed upon ligand-
macromolecule binary complex formation at constant temperature
and pressure (Fig. 6). The ITC data also provide thermodynamic sig-
natures of non-covalent interactions of substrate(s)/product(s)
binding to MtGMPS. The measure of heat released upon binding
of the ligands allowed the determination of the binding enthalpy
(DH) of the process, the stoichiometry of the interaction (n), and
the association constant at equilibrium (Ka). The dissociation con-
stant at equilibrium (Kd) could be calculated as the inverse of Ka
(Kd = 1/Ka). Furthermore, the Gibbs free energy (DG) and entropy
of binding (DS) were determined from the association constant
values at equilibrium as described by Eq. (7). The overall binding
isotherms for XMP, ATP, and glutamine were best ﬁtted to a model
of one set of sites assuming that the substrates bind to the mono-
mer with the same afﬁnity in all active sites (Table 2). The rather
large standard errors were a direct consequence of the shape of
the binding isotherm, which will dictate how accurate the thermo-
dynamic parameters can be determined. The shape of the binding
isotherm is dependent on Kd and the concentration of the interact-
ing component in the calorimeter cell (the total binding site con-
centration) [28,33]. The product of these two terms gives a
number called the C value, which is given by C = nKB[component
2], where n represents the stoichiometry of the interaction, KB is
the equilibrium binding constant and [component 2] the total con-
centration of binding sites. The latter is limited by the need to ob-
tain large quantities and/or solubility. In the concentrations
regimes usually adopted for ITC experiments, the data sets with
low C values tend to rather featureless lines due to little changes
inDH values from injection to injection. As it is important to obtain
an isotherm that provides maximum data points for the ﬁtting pro-
cess, the loss of the plateau at the beginning of the titration curve
due to low C values might have contributed to the large standard
errors.
The PPi binding isotherm (Fig. 6D) was not sufﬁciently deﬁned
to provide an adequate ﬁt of the data to any model, probablybecause this substrate may exert different and simultaneous
effects on MtGMPS. Moreover, the rather large temperature
(40 C) in the assay generated an elevated dilution heat, affecting
the reading and collection of constants. At any rate, binding of
PPi to free MtGMPS could be detected by ITC measurements
(Fig. 6D). The ITC results show that XMP (Fig. 6A) and ATP
(Fig. 6B) bind to the free enzyme in the presence of Mg2+, which
suggests a random mechanism of binding of both substrates to
the ATPPase domain of MtGMPS. Glutamine, the substrate hydro-
lyzed by the GATase domain of MtGMPS, binds to free enzyme
(Fig. 6C). No binding of either GMP, AMP, or glutamate to free en-
zyme could be detected by ITC (insets of Fig. 6A, B, and C, respec-
tively). The ITC data thus suggest that substrate binding is random
and PPi is the last product to be released to yield free enzyme.
However, an order for release of glutamate, AMP, and GMP could
not be derived from the ITC data. An ordered mechanism has been
proposed for human GMPS [37], in which MgATP binding is fol-
lowed by XMP, and glutamine is the last substrate to bind, whereas
PPi is the last product to be released to yield free enzyme. A steady-
state ordered addition of MgATP followed by XMP to ATPPase do-
main of P. falciparum GMPS has been proposed based on product
inhibition studies [15]. In addition, glutamine binding to P. falcipa-
rum GMPS enzyme appears to be independent of the binding of
ATP and XMP, as for MtGMPS, and glutamate is the ﬁrst product
to be released, followed by AMP, GMP, and PPi [15]. On the other
hand, a different order of substrate binding has been proposed
based on the crystal structure of E. coli GMPS, in which XMP bind-
ing is followed by MgATP, and glutamine is the last substrate to
bind to the enzyme [36].
The glutaminase activity assay was carried out to determine
whether hydrolysis of glutamine to NH3 and glutamate occurs in
the absence of XMP and ATP. Although the ITC data showed that
glutamine binds to free MtGMPS, no glutaminase activity could
be detected in the absence of XMP and ATP. To achieve the enzy-
matic conformation for hydrolysis of glutamine, it is necessary
for XMP and ATP substrates to be present in the binding site
[14,36]. This is consistent with the proposal that GMPS has poor
glutaminase activity in the absence of XMP and ATP to guarantee
that hydrolysis of glutamine is tightly coupled with product forma-
tion, thereby preventing indiscriminate conversion of glutamine to
NH3 and glutamate [15,36]. Formation of adenyl-XMP reaction
intermediate in the ATPPase domain has been proposed to signal
the glutaminase domain for complete activity, leading to channel-
ing of NH3 formed in the GATase to ATPPase domain only in the
presence of adduct in the latter [15].
Multiple sequence alignment
The polypeptide sequences of prokaryotic and eukaryotic
GMPSs, to which three-dimensional structures have been reported,
were included in the primary sequence comparison analysis car-
ried out using Clustal W (Fig. 7). Namely, the two-domain type
GMPS proteins from E. coli (PDB ID: 1GPM) [36] and Homo sapiens
(PDB ID: 2VXO; Welin et al., unpublished results), and the ATPPase
subunit of two-subunit type GMPS protein from the hyperthermo-
philic archaeon P. horikoshii OT3 (PDB ID: 3A4I) [17]. This analysis
suggests that the residues of the Cys-His-Glu catalytic triad in the
N-terminal Class I amidotransferase domain of E. coli GMPS [36]
are conserved in MtGMPS, namely Cys93, His179, and Glu181 (M.
tuberculosis numbering) (Fig. 7). By analogy to many hydrolytic en-
zymes, it has been proposed that the His residue of the Cys-His-Glu
catalytic triad serves as a general base in the nucleophilic attack of
Cys side chain on the amide carbon of glutamine [36]. In addition,
MtGMPS contains a glycine-rich ATP-binding motif called the ‘‘P-
loop’’ (residues 233–239; SGGVDSS) (Fig. 7), which is strictly con-
served in the ATPPase subunits/domains of GMPS proteins [17,36].
Fig. 6. Isothermal titration calorimetric (ITC) curves for binding of ligands to MtGMPS (80 lM). (A) Titration of XMP at a ﬁnal concentration of 1.5 mM. (B) Titration of ATP at a
ﬁnal concentration of 1.5 mM. (C) Titration of glutamine at a ﬁnal concentration of 3.5 mM. (D) Titration of PPi at a ﬁnal concentration of 1.5 mM. The insets are titration of (A)
GMP, (B) AMP, and (C) glutamate, respectively. The same scale was employed for the Y-axis of large panels and insets.
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phosphatase family. The members of this family have structurallyhomologous ATP-binding domains and a common mechanism in
which the carboxyl or carbonyl groups are activated by adenyla-
Table 2
Association constants and thermodynamic parameters of different ligands binding to MtGMPS.
Ligands n DH (kcalmol1) DG (kcalmol1) DS (calmol1K1) Kd (M)
XMP 1 14.9 ± 0.6 7 ± 4 25.1 18 (±3)  106
ATP 1 3 ± 5 7 ± 5 13.0 24 (±18)  106
Glutamine 1 16 ± 2 3.4 ± 0.4 39.6 2.0 (±0.3)  103
n = number of sites, DH = binding enthalpy, DG = Gibbs free energy, DS = binding entropy, Kd = equilibrium dissociation constant.
Fig. 7. Multiple sequence alignment of polypeptide chains of GMPS enzymes. Completely and highly conserved residues are boxed and indicated by black letters on a gray
background and white letters on a gray background, respectively. Triangles and circles indicate the putative binding residues for ATP and XMP, respectively. Diamonds
indicate residues forming intermolecular hydrogen bonds in homodimers of P. horikoshii (ATPPase domain), E. coli, and M. tuberculosis GMPS enzymes. Sequence alignment
was obtained with Clustal W.
T.M.A. Franco et al. / Archives of Biochemistry and Biophysics 517 (2012) 1–11 9tion (releasing PPi) followed by attack of a nitrogen nucleophile
releasing AMP [36]. The largest differences between the primary
sequences of prokaryotic and eukaryotic GMPS proteins map tothe C-terminal amino acids of the dimerization domain [36].
Monomeric eukaryotic GMPS has several large insertions as com-
pared to prokaryotes, which are thought to form an additional
10 T.M.A. Franco et al. / Archives of Biochemistry and Biophysics 517 (2012) 1–11domain that eliminates the need for dimerization. The residues
Arg509, Val510, Tyr512, Asp513, and Thr521, which form intermo-
lecular hydrogen bonds, are conserved in P. horikoshii and E. coli
(Fig. 7). These residues are also conserved inM. tuberculosis and hu-
mans with the exception of Val510 (Ile in humans) and Leu512 in
M. tuberculosis, which are obviously not involved in dimerization in
the crystal (PDB ID: 2VXO) of monomeric human GMPS [14]. The
dimerization domain is adjacent to the ATP-binding site of the
ATPPase domain. Contacts between the domains are highly con-
served, including the proline- and glycine-rich linker peptide (res-
idues 403–408), which in E. coli (PDB ID: 1GPM) is anchored in the
dimerization domain by the speciﬁc contacts of invariant residues
[36]. On the other hand, all residues of the putative XMP-recogniz-
ing amino acid residues are conserved between the polypeptide
sequences included in the alignment (Fig. 7). MtGMPS has fairly
high identity to prokaryotic GMPSs (M. tuberculosis and E. coli
GMPSs: 47.39%; M. tuberculosis and P. horikoshii GMPSs: 31.81%),
and relatively low identity to the human protein (M. tuberculosis
and human GMPSs: 15.50%).Conclusions
Particular features of M. tuberculosis, such as enzymes of either
essential metabolic pathways exclusive to the microorganism [40]
or nucleotide salvage pathways [12,41] with unique characteristics
as compared to the human host can be explored to direct efforts
towards developing new strategies to combat TB. Purine biosyn-
thetic enzymes, including MtGMPS, are considered to be attractive
targets for the development of new auxotrophic strains or novel
anti-mycobacterial agents [8,12,13,42]. Although the guaA gene
has been predicted by in silico analysis of M. tuberculosis genome
sequence to encode a protein with GMPS activity, no formal bio-
chemical data have been presented to lend support to this compu-
tational prediction. To pave the way for further efforts to show
whether or not deletion of the guaA gene may result in an auxotro-
phic M. tuberculosis strain with attenuated virulence, the present
work presents biochemical data on guaA-encoded MtGMPS.
Vaccines are widely recognized to be one of the most important
medical advances in history. However, the ﬁeld of TB vaccine faces
formidable scientiﬁc and policy challenges. A recently published
study undertaken by Aeras to assess the barriers and drivers to
the introduction of new TB vaccines arrived at the following con-
clusions [43]: ‘‘a collaborative approach to solving scientiﬁc, policy,
and resource obstacles – as well as new partnerships among
emerging economies and vaccine development organizations – will
be critical to developing a new TB vaccine that could achieve its
public health potential to save lives and reduce the burden of dis-
ease’’. Accordingly, the work reported here represents a ﬁrst step
towards further efforts to showwhether or not deletion of the guaA
gene may result in an auxotrophicM. tuberculosis strain with atten-
uated virulence. It is also hoped that the biochemical data here pre-
sented may contribute to functional genomic efforts. In addition,
understanding the mode of action of MtGMPS may be useful to
chemical biologists interested in designing function-based chemi-
cal compounds to elucidate the biological role of this enzyme in
the context of whole M. tuberculosis cells.
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